Caris Life Sciences, Inc. (CAI)
25.23
-0.80
(-3.07%)
USD |
NASDAQ |
Nov 06, 16:00
25.15
-0.08
(-0.32%)
After-Hours: 20:00
Caris Life Sciences Total Long Term Debt (Quarterly) : 456.73M for Sept. 30, 2026
Total Long Term Debt (Quarterly) Chart
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 456.73M |
| June 30, 2026 | 446.04M |
| March 31, 2026 | 425.12M |
| December 31, 2025 | 421.33M |
| September 30, 2025 | 420.29M |
| June 30, 2025 | 411.69M |
| Date | Value |
|---|---|
| March 31, 2025 | 413.80M |
| December 31, 2024 | 418.18M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Natera, Inc. | 142.62M |
| Myriad Genetics, Inc. | 201.60M |
| BioRestorative Therapies, Inc. | 0.00 |
| CareDx, Inc. | 20.32M |
| Exagen, Inc. | 26.68M |